{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:05:11Z","timestamp":1792807511953,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Liaoning Provincial Science and Technology Program Joint Program","award":["2024JH2\/102600190"],"award-info":[{"award-number":["2024JH2\/102600190"]}]},{"name":"Dalian University of Technology - Liaoning Cancer Hospital Medical Engineering Cross Joint Fund","award":["LD2023021"],"award-info":[{"award-number":["LD2023021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02726-4","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:44:25Z","timestamp":1759218265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of different neoadjuvant radiotherapy doses on survival outcomes and toxicity in patients with locally advanced rectal cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Weiting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuming","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hujian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-6815","authenticated-orcid":false,"given":"Yanli","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2726_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2726_CR2","doi-asserted-by":"publisher","first-page":"2236364","DOI":"10.1080\/19490976.2023.2236364","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Dan W, Zhang N, et al. Colorectal cancer and gut microbiota studies in China. Gut Microbes. 2023;15:2236364.","journal-title":"Gut Microbes"},{"key":"2726_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702\u201315.","journal-title":"Lancet Oncol"},{"key":"2726_CR4","doi-asserted-by":"publisher","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","volume":"28","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22\u201340.","journal-title":"Ann Oncol"},{"key":"2726_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"2726_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.7150\/ijbs.15438","volume":"12","author":"Y Li","year":"2016","unstructured":"Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016;12:1022\u201331.","journal-title":"Int J Biol Sci"},{"key":"2726_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/bjs.7315","volume":"98","author":"HA Swellengrebel","year":"2011","unstructured":"Swellengrebel HA, Marijnen CA, Verwaal VJ, et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg. 2011;98:418\u201326.","journal-title":"Br J Surg"},{"key":"2726_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679\u201387.","journal-title":"Lancet Oncol"},{"key":"2726_CR9","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","volume":"26","author":"M Braendengen","year":"2008","unstructured":"Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26:3687\u201394.","journal-title":"J Clin Oncol"},{"key":"2726_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340.","journal-title":"N Engl J Med"},{"key":"2726_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol. 2010;28:1638\u201344.","journal-title":"J Clin Oncol"},{"key":"2726_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.14740\/gr681w","volume":"8","author":"E Peponi","year":"2015","unstructured":"Peponi E, Skloupiotis V, Tsironis D, et al. Preoperative chemoradiation in locally advanced rectal cancer: efficacy and safety. Gastroenterol Res. 2015;8:303\u20138.","journal-title":"Gastroenterol Res"},{"key":"2726_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"2726_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.radonc.2014.10.006","volume":"113","author":"A Sainato","year":"2014","unstructured":"Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223\u20139.","journal-title":"Radiother Oncol"},{"key":"2726_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00066-014-0650-0","volume":"190","author":"O Hernando-Requejo","year":"2014","unstructured":"Hernando-Requejo O, L\u00f3pez M, Cubillo A, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol. 2014;190:515\u201320.","journal-title":"Strahlenther Onkol"},{"key":"2726_CR16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3906\/sag-1812-185","volume":"49","author":"N Jankarashvili","year":"2019","unstructured":"Jankarashvili N, Kakhadze S, Topeshashvili M, et al. Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer. Turk J Med Sci. 2019;49:1484\u20139.","journal-title":"Turk J Med Sci"},{"key":"2726_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2012.05.017","volume":"85","author":"AL Appelt","year":"2013","unstructured":"Appelt AL, Pl\u00f8en J, Vogelius IR, et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:74\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2726_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2025.104627","volume":"29","author":"Y Pointreau","year":"2025","unstructured":"Pointreau Y, Blanchard N, Chamois J, et al. Real-world evidence for preoperative use of (chemo)radiotherapy with intensity modulation for locally advanced rectal cancer by the Colib French group. Cancer Radiother. 2025;29:104627.","journal-title":"Cancer Radiother"},{"key":"2726_CR19","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/codi.15512","volume":"23","author":"J On","year":"2021","unstructured":"On J, Shim J, Mackay C, et al. Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. Colorectal Dis. 2021;23:1326\u201333.","journal-title":"Colorectal Dis"},{"key":"2726_CR20","first-page":"212","volume":"21","author":"HS Ryu","year":"2022","unstructured":"Ryu HS, Lee JL, Kim CW, et al. Correlative significance of tumor regression grade and ypT category in patients undergoing preoperative chemoradiotherapy for locally advanced rectal cancer. Clin Colorectal Cancer. 2022;21:212\u20139.","journal-title":"Clin Colorectal Cancer"},{"key":"2726_CR21","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1002\/onco.13707","volume":"26","author":"HY Chen","year":"2021","unstructured":"Chen HY, Feng LL, Li M, et al. College of American Pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer. Oncologist. 2021;26:e780\u201393.","journal-title":"Oncologist"},{"key":"2726_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s12094-023-03343-x","volume":"26","author":"Y Cui","year":"2024","unstructured":"Cui Y, Liu X, Li S, et al. The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0. Clin Transl Oncol. 2024;26:1012\u201321.","journal-title":"Clin Transl Oncol"},{"key":"2726_CR23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.21873\/invivo.11997","volume":"34","author":"JH Baek","year":"2020","unstructured":"Baek JH, Baek DW, Kang BW, et al. Prognostic impact of the neoadjuvant rectal score as compared with the tumor regression grade and yield pathologic TNM stage in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. In Vivo. 2020;34:1993\u20139.","journal-title":"In Vivo"},{"key":"2726_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.surg.2019.06.009","volume":"166","author":"T Tominaga","year":"2019","unstructured":"Tominaga T, Akiyoshi T, Yamamoto N, et al. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Surgery. 2019;166:1061\u20137.","journal-title":"Surgery"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:03:36Z","timestamp":1759262616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2726"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02726-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved anonymized patient data and, due to its retrospective nature, was exempt from the requirement for informed consent. This study was approved by the Ethics Committee of Liaoning Cancer Hospital (KY20231116), in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and constant to participate"}},{"value":"All authors have consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}